Business context and reporting period
Oculis Holding AG’s Form 20-F reports the fiscal year ended December 31, 2022, not a standalone 2022 fourth quarter. The audited financial statements are for predecessor Oculis SA and subsidiaries, prepared under IFRS and presented in Swiss francs (CHF). Oculis is a clinical-stage ophthalmology biopharmaceutical company with no approved products and no product-sales revenue.
The business combination with European Biotech Acquisition Corp. (EBAC) closed on March 2, 2023, after the reporting period. Oculis shares and warrants began Nasdaq trading on March 6, 2023.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Product-sales revenue | None | None |
| Grant income | CHF 0.9 million | CHF 1.0 million |
| Research and development expense | CHF 22.2 million | CHF 9.6 million |
| General and administrative expense | CHF 11.1 million | CHF 4.6 million |
| Operating loss | CHF 32.4 million | CHF 13.2 million |
| Net loss | CHF 38.7 million | CHF 18.6 million |
| Net cash used in operating activities | CHF 25.1 million | CHF 13.8 million |
| Cash and cash equivalents at year-end | CHF 19.8 million | CHF 46.3 million |
Operating margin and other revenue-based margins are not meaningful because revenue consisted only of grants and the company had no product sales. Finance expense was CHF 6.4 million, mainly accrued preferred-share dividends classified as interest expense under IFRS. The resulting net loss was CHF 38.7 million, or CHF 12.94 per share.
At December 31, 2022, total assets were CHF 37.1 million, current assets CHF 23.7 million, current liabilities CHF 12.0 million, and total liabilities CHF 135.1 million. Long-term financial liabilities were CHF 122.4 million, principally preferred shares and accrued dividends; total equity was negative CHF 98.0 million. Operating cash use increased as clinical and development spending rose. Investing activities used CHF 3.5 million, largely for the OCS-05 license; financing activities provided CHF 1.7 million.
Management stated that year-end cash was expected to fund operations for at least 12 months. Separately, the March 2023 business combination, PIPE financing and conversion of convertible loans generated disclosed gross proceeds of approximately CHF 97.4 million. The filing also reports CHF 16.7 million of estimated transaction costs. Management said post-closing resources were expected to fund planned operations beyond 12 months, while cautioning that estimates depend on assumptions and additional funding may be needed.
Material changes versus the prior comparable period
- Net loss more than doubled from CHF 18.6 million to CHF 38.7 million; operating loss increased 145%.
- R&D expense rose 132%, primarily reflecting two Phase 3 OCS-01 trials and other candidate development, including OCS-05. General and administrative expense increased 139%, including transaction and public-company preparation costs and added personnel.
- Operating cash use increased 81%, while year-end cash fell CHF 26.5 million. The 2021 financing inflow was substantially larger, principally due to the Series C financing.
- Preferred-share financial liabilities increased from CHF 113.5 million to CHF 122.4 million, including accrued interest. The business combination subsequently met the contractual qualifying condition that removed the disclosed April 2025 preferred-share redemption risk; the filing says preferred shares would transfer to equity, including accrued dividends.
Outlook, commentary and key risks
- Development outlook: OCS-01 was in Phase 3 trials for diabetic macular edema (DME) and post-cataract-surgery inflammation and pain. The filing expected initial trial readouts in mid-2023. OCS-02 Phase 2b trials for dry eye disease and non-infectious anterior uveitis were planned for 2023, with results expected in 2024. OCS-05 was being studied in a first-in-patient acute optic neuritis trial in France; FDA-enabling toxicology remained a key hurdle after an earlier FDA clinical hold.
- Funding and execution: Oculis expects continued losses and significant R&D spending, has no approved products or sales infrastructure, and may need additional capital. Its pipeline depends heavily on three candidates and on third-party manufacturers, CROs and license agreements.
- Clinical and regulatory risks: Trial results may not predict later-stage outcomes; safety issues, delays, regulatory demands or failure to obtain approval could prevent commercialization. OCS-01 has a known risk of increased intraocular pressure. OCS-05 must satisfy FDA toxicology requirements.
- Other material issues: Management reported ineffective disclosure controls at December 31, 2022, due to a material weakness involving insufficient accounting personnel and financial-close controls. The separate IT-controls weakness was reported as remediated. No material misstatement was identified, but management had not completed a Sarbanes-Oxley internal-control evaluation, and the auditor did not attest to controls.
- Contingencies and unusual items: Potential milestone payments under the Novartis and Accure licenses were up to CHF 89.7 million and CHF 103.6 million, respectively, if milestones are achieved; sales royalties also apply. External research commitments totaled CHF 13.1 million at year-end, including CHF 12.1 million due within one year. The filing reported no material legal proceedings and no product-sales guidance.
Most important facts for investors to verify
- Post-combination cash available after redemptions, transaction costs and operating outflows, and the company’s current cash runway.
- Progress and complete results from both OCS-01 Phase 3 programs, including safety findings and any subsequent regulatory updates.
- Whether planned OCS-02 trials commenced and whether the biomarker strategy is supported by subsequent data.
- FDA status and toxicology plan for OCS-05, including whether the clinical hold requirements have been resolved.
- Remediation of the remaining financial-close control weakness and any later auditor or management assessment of internal controls.
- Potential dilution from the 2023 incentive plan, contingent earn-out shares and 4.4 million warrants outstanding at period-end; warrants have an $11.50 exercise price.